Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Technology Stocks : Lance B's : Its A Beautiful Thing -- Ignore unavailable to you. Want to Upgrade?

To: LANCE B who wrote (2677)	1/7/2000 2:17:00 PM
From: Bryan	Respond to of 4792

ACEL 1 1/8 Does anybody have a clue what is going on with ACEL today? If not, no big deal.....just curious.....I usually don't deal these, so I am clueless with pennies and biotechs in general. But FWIW, check this out: quote.yahoo.com There has not been news on this company since their last 10Q, which was nothing spectacular. There is no chat about Alfacell on YAHOO, but I was able to find an obscure post about them: < Previous \| Next > [ First \| Last \| Msg List ] Reply Gator: Buy ACEL, Cancer Drug Company by: M_Goodtime 12/27/1999 10:35 am EST Msg: 44488 of 44749 Ready to file NDA ----------------------------------------------------------- Posted as a reply to: Msg 44483 by FL98Man < Previous \| Next > [ First \| Last \| Msg List ] Reply messages.yahoo.com I actually called the company and asked them about the price jump. They said they watch the day-to-day price, they saw the spike today, and they would not comment on it. After nagging a bit more about a possible PR, they offered to switch me to the company CEO, but I just ended it there. Thoughts/comments? Regards, B

To: LANCE B who wrote (2677)	1/7/2000 3:55:00 PM
From: Norms	Read Replies (1) \| Respond to of 4792

I just got 20K of CDIK. European or Asian announcement about revolutionary Glaucoma treatment is supposed to be coming next week. People will only go to eye doctor a few times a year for a special treatment which costs the company .18 and sells for $25 each visit. Volume is 10 times normal

To: LANCE B who wrote (2677)	1/8/2000 5:28:00 AM
From: Norms	Respond to of 4792

Guess the CDIK news from a few days ago needed time to sink in for investors. I love this stock as an investment and for what it might do for my daughter who suffered an eye injury last year when a kid threw a rock which hit her eye. European and Asian sales soon and FDA approval around the corner - with a potential audience of 66.8 million people worldwide. I'll take it. I believe that this could hit $1.00 short term and $7-10 by years end with FDA Approval in place. ********************************************************************************* HUGE NEWS- 100% SUCCESS RATE. Monday January 3, 8:04 am Eastern Time Company Press Release Coronado Industries' Medical Director Treats Patients in China With 100% Success Rate for Lowering IOP FOUNTAIN HILLS, Ariz.--(BW HealthWire)--Jan. 3, 2000--Coronado Industries Inc. (OTC BB: CDIK - news; www.coronadoindustries.com) Monday announced that its medical director, Leo D. Bores, M.D., treated 29 glaucoma patients on a recent trip to Xian, China. All of the patients treated experienced a lowering of intraocular pressure (IOP) as a result of treatment with Coronado's patented technology, pneumatic trabeculoplasty(TM) (PNT(TM)). Follow up with the patients since the treatment indicates that the IOP has remained lower as a result of the treatment. Bores hosted a seminar on the PNT(TM) technology at a medical symposium in Xian Dec. 11, 1999. Everblooming Enterprises, a major distributor of ophthalmic devices in China, sponsored the trip. The Chinese Medical Association's Glaucoma team and top ophthalmologists from Beijing, Shanghai, and several other major provinces attended the seminar. Chinese National Television also broadcast a story on his visit and the technology. ''This is an important step toward introducing Coronado's PNT(TM) device into the healthcare community and major hospitals of China,'' said Gary Smith, president of Coronado Industries. ''The latest statistics show that 7 to 9 million people in China suffer from glaucoma and approximately 25 percent or 2 million are children.'' Bores also demonstrated the PNT(TM) technology for top Chinese military officials and was allowed unprecedented access at military bases in China. Based on the success of this first trip, Bores has been invited back to China in February. He is expected to visit major hospitals in Hong Kong and Singapore and conduct symposiums on glaucoma and the PNT(TM) technology for groups of physicians and other influential government officials. Bores' return trip will kick off Everblooming Enterprises' marketing campaign as a distributor of the PNT(TM) products in China. ''This can prove to be a valuable revenue stream for our company,'' said G. Richard Smith, CEO of Coronado industries. Approximately 66.8 million people worldwide suffer from primary glaucoma according to a Johns Hopkins University School of Medicine study. Glaucoma is a progressive disease and is the second leading cause of blindness. More than 7.5 million Americans suffer from Glaucoma. Glaucoma occurs when the optic nerve is damaged by high intraocular pressure (IOP). The optic nerve is responsible for sending impulses to the brain, which translates those signals into sight. When the nerve is damaged, the signals cease to be transmitted and loss of vision occurs. Currently, patients rely on eye drops or surgery to lower IOP. Coronado Industries' PNT(TM) technology is a non-invasive medical procedure that lessens, if not eliminates patients' dependence on drops without the risk and cost of surgery. Applicable to open-angle and pigmentary glaucoma, the two most common types of glaucoma, PNT(TM) uses a suction device that is applied to the eye for 1 to 2 minutes. The treatment is proven safe and effective with no known side effects and is less costly than traditional therapies. Often one treatment is sufficient, but there is no risk in subsequent treatments if needed, as frequently as every three months. Evaluation of approximately four years of data from an ongoing study of patients receiving PNT(TM) has shown the procedure, originally designed to treat Primary Open Angle Glaucoma (POAG), pigmentary glaucoma and glaucoma associated with pseudoexfoliation of the lens capsule, is of value in treating ocular hypertension, as well. Safe Harbor Statement The statements contained in this release which are not historical are forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those expressed in the forward-looking statements, including, but not limited to, certain delays beyond the company's control with respect to market acceptance of new technologies and products, delays in testing and evaluation of products, and other risks detailed from time to time in the company's filings with the Securities and Exchange Commission. Coronado Industries, through its two wholly owned subsidiaries American Glaucoma and Ophthalmic International, manufactures devices to treat forms of glaucoma and offers glaucoma diagnosis and treatment under an I.D.E Study (Investigational Device Exemption). Pending FDA approval, Coronado will license its patented treatment procedure and equipment in the United States. Coronado's Pneumatic Trabeculoplasty (PNT(TM)) procedure uses a non-invasive, patented, low-cost pneumatic device that has proven to be an effective and safe treatment option for glaucoma. In December 1998, Coronado was granted a CE Mark from the European Commission, which serves as a ''passport'' to allow a manufacturer to freely sell its products within the European Marketplace. Contact: Coronado Industries Inc., Fountain Hills G. Richard Smith, 480/837-6810 or Market Pathways Shannon T. Squyres, 949/955-1860 More Quotes and News: Coronado Industries Inc (OTC BB:CDIK.OB - news) Related News Categories: health care, medical/pharmaceutical